InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET | InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
Logo-InveniAI.png
InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration
April 27, 2021 08:10 ET | InveniAI LLC
Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discoveryShionogi will synthesize and develop compounds for targets identified...
Logo-InveniAI.png
InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration
December 09, 2020 08:10 ET | InveniAI
Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin’s antibody technologyKyowa Kirin will select multiple programs...
Logo-InveniAI.png
InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways
September 09, 2020 08:10 ET | InveniAI
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...
Logo-InveniAI.png
Tackling Tuberculosis with AI: Novel TBMeld® Platform to Transform Research in the Prevention and Treatment of Tuberculosis
July 31, 2020 08:00 ET | InveniAI
-InveniAI announces partnership with the Mueller Health Foundation (MHF) to create a first of its kind AI-driven platform to be used for the discovery, tracking, and evaluation of 1) novel TB...
Logo-InveniAI.png
InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare
July 29, 2020 08:30 ET | InveniAI
Three-year strategic collaboration to leverage InveniAI’s AI- and ML-powered Platform, AlphaMeld® after a successful proof-of-value collaborationAlphaMeld® will capture consumer-specific innovation...
Logo-InveniAI.png
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
June 02, 2020 08:00 ET | InveniAI
GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across...
Logo-InveniAI.png
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite
November 06, 2019 08:00 ET | InveniAI
GUILFORD, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
Logo-InveniAI.png
InveniAI Launches Suite of Products Powered by AlphaMeld™, an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences
September 17, 2019 08:30 ET | InveniAI
- CIMeld™, an AlphaMeld™ powered product for competitive/business intelligence, is set to launch at PharmaCI USA 2019 - Tailored suite of products to address high value questions accelerating...
Logo-InveniAI.png
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU
July 02, 2019 08:31 ET | InveniAI
 Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI establishes presence in Basel, Switzerland...